Tumor Biology

, Volume 35, Issue 5, pp 4529–4538 | Cite as

GH1 T1663A polymorphism and cancer risk: a meta-analysis of case–control studies

  • Jing Shi
  • Jian-Huan Tong
  • Shuang Cai
Research Article


Many studies have demonstrated that the most common polymorphism (T1663A, rs2665802) in the promoter region of growth hormone 1 (GH1) gene might play an important role in cancer development and progression. This meta-analysis aims to investigate a more precise estimation of the relationship between GH1 T1663A polymorphism and cancer risk. We searched CISCOM, CINAHL, Web of Science, PubMed, Google Scholar, EBSCO, Cochrane Library, and CBM databases from inception through October 1st, 2013. Meta-analysis was performed using the STATA 12.0 software. Seven studies were included with a total of 4,018 cancer patients and 5,308 healthy controls. Our meta-analysis results revealed that GH1 T1663A polymorphism was associated with increased cancer risks. Subgroup analysis by cancer type showed significant associations between GH1 T1663A polymorphism and increased colorectal cancer risk, but there was no evidence of any association with breast cancer. Further subgroup analysis based on ethnicity indicated that GH1 T1663A polymorphism might increase cancer risks among Asian populations. However, no statistically significant association was found among Caucasian populations. Meta-regression analyses also suggested that cancer type and ethnicity may be the main sources of heterogeneity. No publication bias was detected in this meta-analysis. The present meta-analysis indicates that GH1 T1663A polymorphism may contribute to the risk of colorectal cancer, especially among Asian populations.


Cancer Growth hormone 1 Single nucleotide polymorphism Susceptibility Meta-analysis 



We thank all our colleagues working in the Department of Medical Oncology, the First Hospital of China Medical University. This work was supported by a grant from the Scientific Research Project Foundation of Liaoning Provincial Education Department (no. 05L570). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Gohlke JM, Thomas R, Zhang Y, Rosenstein MC, Davis AP, Murphy C, et al. Genetic and environmental pathways to complex diseases. BMC Syst Biol. 2009;3:46.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Schottenfeld D, Beebe-Dimmer JL. Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions. Annu Rev Public Health. 2005;26:37–60.CrossRefPubMedGoogle Scholar
  4. 4.
    Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4(3):177–83.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bartsch H, Dally H, Popanda O, Risch A, Schmezer P. Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res. 2007;174:19–36.CrossRefPubMedGoogle Scholar
  6. 6.
    Poling JS, Phillips 3rd JA, Cogan JD, Hamid R. Pharmacologic correction of dominant-negative GH1 deficiency causing mutations. Clin Transl Sci. 2011;4(3):175–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gao CM, Gong JP, Wu JZ, Cao HX, Ding JH, Zhou JN, et al. Relationship between growth hormone 1 genetic polymorphism and susceptibility to colorectal cancer. J Hum Genet. 2010;55(3):163–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Millar DS, Horan M, Chuzhanova NA, Cooper DN. Characterisation of a functional intronic polymorphism in the human growth hormone (gh1) gene. Hum Genomics. 2010;4(5):289–301.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wolf A, Millar DS, Caliebe A, Horan M, Newsway V, Kumpf D, et al. A gene conversion hotspot in the human growth hormone (GH1) gene promoter. Hum Mutat. 2009;30(2):239–47.CrossRefPubMedGoogle Scholar
  10. 10.
    Alfred T, Ben-Shlomo Y, Cooper R, Hardy R, Cooper C, Deary IJ, et al. A multi-cohort study of polymorphisms in the GH/IGF axis and physical capability: the HALCyon programme. PLos One. 2012;7(1):e29883.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Le Marchand L, Donlon T, Seifried A, Kaaks R, Rinaldi S, Wilkens LR. Association of a common polymorphism in the human GH1 gene with colorectal neoplasia. J Natl Cancer Inst. 2002;94(6):454–60.CrossRefPubMedGoogle Scholar
  12. 12.
    Wernli KJ, Newcomb PA, Wang Y, Makar KW, Shadman M, Chia VM, et al. Body size, IGF and growth hormone polymorphisms, and colorectal adenomas and hyperplastic polyps. Growth Hormig IGF Res. 2010;20(4):305–9.CrossRefGoogle Scholar
  13. 13.
    Ren Z, Cai Q, Shu XO, Cai H, Cheng JR, Wen WQ, et al. Genetic polymorphisms in the human growth hormone-1 gene (GH1) and the risk of breast carcinoma. Cancer. 2004;101(2):251–7.CrossRefPubMedGoogle Scholar
  14. 14.
    McElholm AR, McKnight AJ, Patterson CC, Johnston BT, Hardie LJ, Murray LJ. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence. Gastroenterology. 2010;139(1):204–12. e3.CrossRefPubMedGoogle Scholar
  15. 15.
    Jia YB, Zhang JZ, Bao XQ, Yan Y. Relationship between a polymorphism in the growth hormone1 gene and gastric cardia adenocarcinoma. J Baot Med Coll. 2008;24(6):555–6.Google Scholar
  16. 16.
    Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, et al. Strengthening the reporting of observational studies in epidemiology–molecular epidemiology (STROBE-ME): an extension of the strobe statement. PLos Med. 2011;8(10):e1001117.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Dupont WD, Plummer Jr WD. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11(2):116–28.CrossRefPubMedGoogle Scholar
  18. 18.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMedGoogle Scholar
  19. 19.
    Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.CrossRefPubMedGoogle Scholar
  20. 20.
    Wagner K, Hemminki K, Grzybowska E, Bermejo JL, Butkiewicz D, Pamula J, et al. Polymorphisms in the growth hormone receptor: a case–control study in breast cancer. Int J Cancer. 2006;118(11):2903–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Gong JP, Gao CM, Takezak T, Wu JZ, Ding JH, Liu YT, et al. Relationship between growth hormone 1 genetic polymorphism and smoking, alcohol drinking and the susceptibility of colorectal cancer. China J Cancer Prev Treat. 2006;13(15):1134–7.Google Scholar
  22. 22.
    Cao G, Lu H, Feng J, Shu J, Zheng D, Hou Y. Lung cancer risk associated with Thr495Pro polymorphism of GHR in Chinese population. Jpn J Clin Oncol. 2008;38(4):308–16.CrossRefPubMedGoogle Scholar
  23. 23.
    Filopanti M, Olgiati L, Mantovani G, Corbetta S, Arosio M, Gasco V, et al. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J Clin Endocrinol Metab. 2012;97(2):E165–72.CrossRefPubMedGoogle Scholar
  24. 24.
    Renehan AG, Solomon M, Zwahlen M, Morjaria R, Whatmore A, Audi L, et al. Growth hormone receptor polymorphism and growth hormone therapy response in children: a Bayesian meta-analysis. Am J Epidemiol. 2012;175(9):867–77.CrossRefPubMedGoogle Scholar
  25. 25.
    Wagner K, Hemminki K, Israelsson E, Grzybowska E, Klaes R, Chen B, et al. Association of polymorphisms and haplotypes in the human growth hormone 1 (GH1) gene with breast cancer. Endocrinol Relat Cancer. 2005;12(4):917–28.CrossRefGoogle Scholar
  26. 26.
    Jia YB, Zhang JZ, Wang Q. Association study of single nucleotide polymorphism in the growth hormone 1 gene and esophageal cancer. J Baot Med Coll. 2008;24(4):335–7.Google Scholar
  27. 27.
    Jia YB, Zhang JZ, Bao XQ, Yan Y. Relationship between a polymorphism in the growth hormone1 gene and gastric cardia adenocarcinoma. J Baot Med Coll. 2008;24:555–6.Google Scholar
  28. 28.
    Khoury-Shakour S, Gruber SB, Lejbkowicz F, Rennert HS, Raskin L, Pinchev M, et al. Recreational physical activity modifies the association between a common GH1 polymorphism and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3314–8.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Boillot C, et al. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2316–25.CrossRefPubMedGoogle Scholar
  30. 30.
    Walenkamp MJ, Wit JM. Genetic disorders in the GH IGF-I axis in mouse and man. Eur J Endocrinol. 2007;157 Suppl 1:S15–26.CrossRefPubMedGoogle Scholar
  31. 31.
    Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene–environment interactions. J Clin Oncol. 2000;18(11):2309–15.CrossRefPubMedGoogle Scholar
  32. 32.
    Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36(3):131–49.CrossRefPubMedGoogle Scholar
  33. 33.
    O’Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009;15(15):4806–14.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Park JH, Wacholder S, Gail MH, Peters U, Jacobs KB, Chanock SJ, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010;42(7):570–5.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Hunter DJ. Gene–environment interactions in human diseases. Nat Rev Genet. 2005;6(4):287–98.CrossRefPubMedGoogle Scholar
  36. 36.
    Colditz GA, Burdick E, Mosteller F. Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary. Am J Epidemiol. 1995;142(4):371–82.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Medical OncologyThe First Hospital of China Medical UniversityShenyangChina
  2. 2.Department of Drug Clinical TrailThe First Hospital of China Medical UniversityShenyangChina
  3. 3.Department of PharmacyThe First Hospital of China Medical UniversityShenyangChina

Personalised recommendations